Topical Finasteride vs Dutasteride, Minoxidil and Oral Finasteride

Key facts

• Compounded topical finasteride with minoxidil is not FDA-approved.
• Finasteride tablets and topical minoxidil are FDA-approved for hair loss. The FDA label for Avodart®, a dutasteride capsule, covers an enlarged prostate, not hair loss.
• There is no FDA finding that topical finasteride works as well as the tablet.
• Trials tested specific study formulas, so their results do not carry over to a different compounded product.
• A provider decides what fits your health history.

How do these options differ?

Each one has a different route and a different FDA status:

• Compounded topical finasteride with minoxidil: a prescription, not FDA-approved
• Propecia® tablets: a prescription, FDA-approved for male pattern hair loss
• Topical minoxidil, such as Rogaine®: over the counter, FDA-approved for hair loss
• Avodart® capsules: a prescription, FDA-approved for an enlarged prostate, with hair loss not on the label

Is topical finasteride as effective as oral?

That is not settled. The FDA has not evaluated the effectiveness of compounded topical finasteride, so there is no FDA finding that it matches the tablet.

One European phase III trial tested a topical spray against placebo, with the oral tablet as a reference. The spray did better than placebo on hair count, and the authors called the change numerically similar to the tablet. Read that with its limits:

• The spray in the trial is not a compounded product, so its result does not carry over to one.
• The oral group was sized to compare DHT in the blood, not hair count.
• Hair counts could be measured in only about half of the men.
• The trial lasted months, and the authors say further studies would help show long-term effect.
• The company behind the spray funded the trial, and several authors worked for it.

The full comparison of topical and oral finasteride covers absorption, side effects and switching.

Topical finasteride vs dutasteride

Dutasteride is a different medicine in the same class, taken by mouth. Avodart® is an FDA-approved capsule. Its FDA label covers symptoms of an enlarged prostate in men, and hair loss is not on it. That label says dutasteride blocks both type 1 and type 2 forms of the enzyme. The label for Propecia®, the oral tablet, says finasteride acts mainly on type 2.

A 2019 meta-analysis of three trials compared oral dutasteride with oral finasteride. It reported better hair results with dutasteride and similar rates of sexual side effects. It did not test topical finasteride, so it does not tell you how a topical compares.

The Avodart® label carries its own warnings for that capsule. It lists impotence, decreased libido, ejaculation disorders and breast disorders, and says sexual side effects may continue after stopping. It describes a long half-life, tells men not to give blood for months after the last dose, and says women who are or may be pregnant should not handle the capsules because dutasteride can be absorbed through the skin.

CHROMA23® does not offer dutasteride. Your doctor or a dermatologist can tell you whether it fits.

Topical finasteride vs minoxidil

They act differently. Finasteride lowers DHT, and minoxidil acts on the hair growth cycle. Topical minoxidil is FDA-approved and sold over the counter. Compounded topical finasteride needs a prescription and is not FDA-approved.

The American Academy of Dermatology says minoxidil can help early hair loss, and that it tends to be more effective alongside another treatment. It says oral finasteride can be used with minoxidil. That does not describe a compounded topical.

Minoxidil alone has its own side effects, listed on the side effects page. It does not expose you or anyone else to finasteride.

Is the combination better than minoxidil alone?

A 2025 meta-analysis pooled seven small randomized trials of topical minoxidil mixed with finasteride against minoxidil alone, and found the mix did better. Its authors rated the evidence low to moderate in certainty and asked for larger, longer trials.

Those trials tested two-ingredient mixes. Men's Hair Solution has four actives and was not among them, so the results do not carry over to it. Some papers describe a topical as avoiding systemic effects. The FDA says absorption through the skin into the bloodstream is expected, and this guide follows the FDA.

How do you choose between them?

You do not have to choose alone. Start with the FDA's position that compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. Ask your provider whether an FDA-approved option fits you, and why a compounded medicine would be recommended.

A provider looks at your health history, your medicines and what you have tried, then decides what fits. CHROMA23® offers Men's Hair Solution and does not offer Propecia®, Rogaine® or dutasteride. Your doctor or a dermatologist can help you compare those.

Frequently asked questions

About CHROMA23®

CHROMA23® brings weight loss, longevity, sexual health, hair, and skincare into one place. Every prescription decision is made by an independent provider licensed in the patient's state, where available, and every medication is dispensed by a state-licensed pharmacy. The assessment is free. One clear price per plan, shown in full before you pay. The medicine is real. The provider is real.

Sources

1. Piraccini et al.: phase III trial of a topical finasteride spray (Journal of the European Academy of Dermatology and Venereology, 2022)
2. Propecia® (finasteride) oral tablets: FDA label (DailyMed)
3. Avodart® (dutasteride) capsules: FDA label (DailyMed)
4. Zhou et al.: dutasteride compared with finasteride in men with androgenetic alopecia, a meta-analysis (Clinical Interventions in Aging, 2019)
5. Minoxidil-finasteride mixed solution vs minoxidil alone: meta-analysis of randomized trials (Frontiers in Medicine, 2025)
6. Men's Rogaine® (minoxidil) foam: FDA drug facts label (DailyMed)
7. American Academy of Dermatology: what is male pattern hair loss, and can it be treated?
8. American Academy of Dermatology: hair loss diagnosis and treatment
9. FDA alert: potential risks associated with compounded topical finasteride products (April 2025)
10. FDA: compounding and the FDA, questions and answers

Keep reading